These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
246 related articles for article (PubMed ID: 34516238)
41. Aduhelm: Biogen abandons Alzheimer's drug after controversial approval left it unfunded by Medicare. Dyer O BMJ; 2024 Feb; 384():q281. PubMed ID: 38307520 [No Abstract] [Full Text] [Related]
42. US FDA defends approval of Alzheimer's disease drug. Jaffe S Lancet; 2021 Jul; 398(10294):12. PubMed ID: 34217382 [No Abstract] [Full Text] [Related]
43. Lessons Learned from Approval of Aducanumab for Alzheimer's Disease. Heidebrink JL; Paulson HL Annu Rev Med; 2024 Jan; 75():99-111. PubMed ID: 38285515 [TBL] [Abstract][Full Text] [Related]
44. A contentious FDA ruling for Alzheimer's disease. The Lancet Neurology Lancet Neurol; 2021 Aug; 20(8):585. PubMed ID: 34237273 [No Abstract] [Full Text] [Related]
45. Knowledge and Attitudes Concerning Aducanumab Among Older Americans After FDA Approval for Treatment of Alzheimer Disease. Zissimopoulos J; Jacobson M; Chen Y; Borson S JAMA Netw Open; 2022 Feb; 5(2):e2148355. PubMed ID: 35157058 [TBL] [Abstract][Full Text] [Related]
46. Aducanumab: The first targeted Alzheimer's therapy. Yang P; Sun F Drug Discov Ther; 2021; 15(3):166-168. PubMed ID: 34234067 [TBL] [Abstract][Full Text] [Related]
47. Representativeness of Participants Eligible to Be Enrolled in Clinical Trials of Aducanumab for Alzheimer Disease Compared With Medicare Beneficiaries With Alzheimer Disease and Mild Cognitive Impairment. Anderson TS; Ayanian JZ; Souza J; Landon BE JAMA; 2021 Oct; 326(16):1627-1629. PubMed ID: 34499725 [TBL] [Abstract][Full Text] [Related]
48. Aduhelm, the Newly Approved Medication for Alzheimer Disease: What Epidemiologists Can Learn and What Epidemiology Can Offer. Glymour MM; Weuve J; Dufouil C; Mayeda ER Am J Epidemiol; 2022 Jul; 191(8):1347-1351. PubMed ID: 35388413 [TBL] [Abstract][Full Text] [Related]
50. Can we learn lessons from the FDA's approval of aducanumab? Liu KY; Howard R Nat Rev Neurol; 2021 Nov; 17(11):715-722. PubMed ID: 34535787 [TBL] [Abstract][Full Text] [Related]
51. FDA Approval of Aducanumab Divided the Community but Also Connected and United It. Hooker JM ACS Chem Neurosci; 2021 Aug; 12(15):2716-2717. PubMed ID: 34228436 [No Abstract] [Full Text] [Related]
52. Landmark Alzheimer's drug approval confounds research community. Mullard A Nature; 2021 Jun; 594(7863):309-310. PubMed ID: 34103732 [No Abstract] [Full Text] [Related]
53. A carte blanche approval in Alzheimer's. Nat Biotechnol; 2021 Jul; 39(7):781. PubMed ID: 34183862 [No Abstract] [Full Text] [Related]
54. Donanemab: FDA experts recommend approval of Alzheimer's drug. Dyer O BMJ; 2024 Jun; 385():q1327. PubMed ID: 38876494 [No Abstract] [Full Text] [Related]
55. "Real-world" eligibility for aducanumab depends on clinical setting and patients' journey. Padovani A; Caratozzolo S; Rozzini L; Pilotto A; Benussi A; Tedeschi G J Am Geriatr Soc; 2022 Feb; 70(2):626-628. PubMed ID: 34750815 [TBL] [Abstract][Full Text] [Related]
56. The FDA Approves Aducanumab for Alzheimer's Disease, Raising Important Scientific Questions1. de la Torre JC; Gonzalez-Lima F J Alzheimers Dis; 2021; 82(3):881-882. PubMed ID: 34250943 [No Abstract] [Full Text] [Related]